

## **Supporting Information**

### **Supplemental Material**

#### **Antibody information**


The following antibodies were used for western blotting: rabbit anti-occludin (1:1000, Cat. No. 406100, Thermo Fisher), rabbit anti-occludin pS490 (1:500, (1)), mouse anti p-44/42 MAPK (Erk1/2) (Thr202/Tyr204) (1:1000, Cat. No. 9106, Cell Signaling), rabbit anti-p44/42 MAPK (Erk1/2) (1:1000, Cat. No. 91022, Cell Signaling) and mouse anti- $\beta$ -actin (1:10000, Cat. No. 3700, Cell Signaling)

The following antibodies were used for immunofluorescence: mouse anti-occludin-594 AlexaFluor conjugated (1:100, Cat. No. 331594, Thermo Fisher), rabbit anti-claudin-5 (1:100, Cat. No. 341600, Thermo Fisher), rat anti-ZO-1 (1:100, Cat. No. MABT11, Millipore), rat anti-CD45 (1:50, Cat. No. 550539, BD Pharmingen) and goat anti-Iba1 (1:100, Cat. No. NB100-1028, Novus Biologicals), anti-GFP-AF 488 (1:250, Cat. No. A21311, Thermo Fisher) and rabbit anti-RBPMS (1:100, Cat. No. 15187-1-AP, Proteintech)


### **References**

1. Sundstrom JM, Sundstrom CJ, Sundstrom SA, Fort PE, Rauscher RL, Gardner TW, Antonetti DA: Phosphorylation site mapping of endogenous proteins: a combined MS and bioinformatics approach. *J Proteome Res* 2009;8:798-807


## Supplemental Data



**Supplementary figure 1:** (A) Transgenic animals expressing either wild-type occludin (WtOCC) or mutated Ser490 to Ala occludin (S490A OCC) followed by IRES-eGFP at the *rosa26* site were crossed with Tek-Cre allowing for endothelial cell specific expression of Wt or S490A occludin. (B) Representative images of retinal cross-sections of Tek-Cre<sup>-</sup>, Tek-Cre<sup>+</sup>, Tek-Cre<sup>+</sup>; WtOCC<sup>+/+</sup> and Tek-Cre<sup>+</sup>; S490A OCC<sup>+/+</sup> stained for GFP (green), IB4 (purple) and nuclei (blue). Legend: GCL — ganglion cell layer; IPL — inner plexiform layer; INL — inner nuclear layer; OPL — outer plexiform layer; ONL — outer nuclear layer. (C) Occludin protein levels from total retinal lysates from adult Tek-Cre<sup>+</sup> and Tek-Cre<sup>+</sup>; S490A OCC<sup>+/+</sup> mice. (D) Pictures from flat-mounted adult retinas from Tek-Cre<sup>+</sup> and Tek-Cre<sup>+</sup>; S490A OCC<sup>+/+</sup> were stained for the vessel marker IB4. Scale bar: 50 $\mu$ m. (E) Vessel architecture was quantified using an automated software and vessel density, branch points, total vessel length and terminal vessels were determined, n=4. Data are represented as mean  $\pm$  SEM. \*\*\* $P < 0.001$  Two-tailed student's t-test.




**Supplementary figure 2:** Tek-Cre<sup>-</sup>, Tek-Cre<sup>+</sup> and Tek-Cre<sup>+</sup>; WtOCC<sup>+/+</sup> mice were given an intravitreal injection of 200 ng VEGF in one eye and vehicle in the other and retinal vascular permeability to 70-kDa Dextran (A) and FITC-BSA (B) was determined after 36 h of VEGF intravitreal injection, by extracting the extravasated dye into the tissue. Data was normalized to the vehicle injected eye of each mouse. (C) Representative western blot for p-Erk1/2 and t-Erk1/2, 1h after VEGF injection (D) Quantification of the immunoreactive bands, normalized against actin protein levels. (E) Retinas were stained for tight junction protein and flat-mounted, 1h after VEGF injection, n=3. Masked scoring of claudin-5, occludin and ZO-1 border staining, ranking in 5 categories of loss, of at least 4 pictures per retina. (F) Representative images of occludin and ZO-1 staining in the superficial and deep capillary plexus in retina flat mounts, 36h after VEGF injection, n=3-4. Scale bar: 50 $\mu\text{m}$ .




**Supplementary figure 3:** (A) Transgenic mice with floxed endogenous occludin and expressing either WT or S490A mutant occludin under the vascular-specific PDGF $\beta$  promoter were generated. Cre was induced by tamoxifen injection at P3. (B) Whole-mount staining for occludin (red) and vessel marker IB4 (purple),  $n=2$ . Scale bar: 50 $\mu$ m. Legend: SCP – superficial capillary plexus; DCP – deep capillary plexus. PDGF*Cre*<sup>-</sup>; *Occ*<sup>fl/fl</sup> and PDGF*Cre*<sup>+</sup>; *Occ*<sup>fl/fl</sup> mice were given an intravitreal injection of 200 ng VEGF in one eye and vehicle in the other and retinal vascular permeability to FITC-BSA (C) and 70-kDa Dextran (D) was determined after 36 h of VEGF intravitreal injection, by extracting the extravasated dye into the tissue. Data was normalized to the vehicle injected eye of each


mouse. VEGF-induced retinal edema formation was determined by measuring retinal thickness by OCT and % change from baseline was calculated (E).



**Supplementary figure 4:** Diabetes was induced by STZ injection in Tek-Cre<sup>+</sup> and Tek-Cre<sup>+</sup>; S490AOC<sup>+/+</sup> mice. After 4 months of diabetes induction blood glucose levels (A) and body weight (B) were determined. \*\*\**P* < 0.001 One-way ANOVA followed by Sidak's post-hoc test.



**Supplementary figure 5:** Representative confocal images from the deep capillary plexus of retinas stained with vessel marker IB4 (grey), leukocyte marker CD45 (red) and microglia/macrophage marker Iba1 (green). Scale bar: 50 $\mu$ m.



**Supplementary figure 6:** (A) After 4 months of diabetes induction retinal cross sections were stained for RBPMS (green) and Hoechst (blue). Scale bar: 50 $\mu\text{m}$ . (B) Quantification of the number of RBPMS-positive cells \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  One-way ANOVA followed by Sidak's post-hoc test. (C) Representative ERG response elicited from 1.5 cd-s/m<sup>2</sup> log flash intensity from a Tek<sup>+</sup>-Cre control animal.